$ARAV News

Last published 2y ago

2y agoARAVAravive, Inc. to Delist from The Nasdaq Stock MarketGlobeNewswireHOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select
3y agoARAVAravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023GlobeNewswireHOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the
3y agoARAVAravive to Participate in William Blair's Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023GlobeNewswireHOUSTON, July 14, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail
3y agoARAVAravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)GlobeNewswireHOUSTON, June 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that in
3y agoARAVAravive To Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireHOUSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail
3y agoARAVAravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023GlobeNewswireHOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the
3y agoARAVAravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell CarcinomaGlobeNewswireTrial initiation anticipated in 2H 2023 with topline data anticipated in 2H 2025Updated Phase 1b/2 ccRCC data to be presented at ASCO 2023 HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the
3y agoARAVAravive Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewswireOn Track for PROC Pivotal Phase 3 Trial Readout Mid-2023Promising ccRCC Phase 1b/2 Results to Date; Update to be Presented at ASCO 2023Strengthened Management Team with Appointment of Carolina Petrini as Chief Commercial
3y agoARAVAravive to Host Virtual KOL Event on its Late-Stage Oncology Asset BatiraxceptGlobeNewswireHOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced it will host a
3y agoARAVAravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual MeetingGlobeNewswireHOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the
3y agoARAVAVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer - NCT05826015ClinicalTrials.govFrequency and severity of treatment-related adverse events, Serum sAXL and GAS6 ratio, Pharmacokinetic (PK) parameters (including Cmax) as determined from AVB-500 serum levels, (and 5 more...)
3y agoARAVAravive Appoints Carolina Petrini as Chief Commercial OfficerGlobeNewswireHOUSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the
3y agoARAVAravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdatesGlobeNewswireHOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported fourth
3y agoARAVAravive Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic CancerGlobeNewswireDose escalation portion of ongoing Phase 1b/2 pancreatic adenocarcinoma trial initiated, with preliminary results expected in 2H 2023 HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the
3y agoARAVAravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers SymposiumGlobeNewswireHOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the
3y agoARAVAravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian CancerGlobeNewswireTopline data expected mid-2023Potential Biologics License Application (BLA) submission end of 2023 HOUSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, the "Company")), a late clinical-stage
3y agoARAVAravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCCGlobeNewswireHOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the U.S. Food
3y agoARAVAravive To Participate in Piper's 34th Annual Healthcare ConferenceGlobeNewswireHOUSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D.,
3y agoARAVAravive Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireHOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the receipt
4y agoARAVAravive Reports Third Quarter 2022 Financial Results and Provides Corporate UpdatesGlobeNewswireContinued Advancement of Clinical Trials in Platinum Resistant Ovarian Cancer (PROC), Clear Cell Renal Cell Carcinoma and Pancreatic AdenocarcinomaSecured Funding to Take the Company Beyond the PROC Readout in
4y agoARAVAravive Announces Approximately $41.5 Million Private Placement FinancingGlobeNewswireHOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV) ("Company"), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has entered
4y agoARAVAravive Receives Third Development Milestone from 3D MedicinesGlobeNewswireHOUSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Aravive Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6
4y agoARAVAravive to Participate in the Cantor Fitzgerald Oncology & HemOnc ConferenceGlobeNewswireHOUSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and R
4y agoARAVAravive to Participate in H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireHOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and R
4y agoARAVAravive Reports Second Quarter 2022 Financial Results and Provides Corporate UpdatesGlobeNewswireHosted Key Opinion Leader (KOL) Symposium; KOLs Presented Positive Updated Batiraxcept Phase 1b Clear Cell Renal Cell Carcinoma (ccRCC) and Phase 1b Pancreatic Adenocarcinoma Data. Presented Updated Clinical Data at ASCO Showing Continued Best-In-Class
4y agoARAVAravive Appoints Dr. Robert B. Geller as Chief Medical OfficerGlobeNewswireHOUSTON, July 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Dr. Robert B. Geller as Chi
4y agoARAV VTVTAravive Appoints Rudy Howard as Chief Financial OfficerGlobeNewswireHOUSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, the "Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Rudy Howard as Chief Financ
4y agoARAVAravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)GlobeNewswireAbstract selected for oral discussion on Genitourinary Cancer on Saturday, June 4, 2022 Development of biomarker offers the potential of a first in class targeted therapy in renal cancer Company has a registrational path for potential accelerated appr
4y agoARAVAravive to Participate in H.C. Wainwright Global Investment ConferenceGlobeNewswireHOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D, DABT, Chief Executive Officer will pres
4y agoARAVAravive Reports First Quarter 2022 Financial Results and Provides Corporate UpdatesGlobeNewswireReported positive updated data and new biomarker data from Phase 1b Study of Batiraxcept in ccRCC Presented updated modeling data from batiraxcept clinical trials at the AACR annual meeting Dosed first patient in Phase 2 study of batiraxcept in cl
4y agoARAVAravive to Host Key Opinion Leader Symposium on May 11, 2022GlobeNewswireHOUSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that it will host a Key Opinion Leader (KOL) Symposium on the GA
4y agoARAVAravive Announces Poster Presentations at the 2022 ASCO Annual MeetingGlobeNewswireHOUSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of two poster abstracts at the upcoming Ameri
4y agoARAVAravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswireHOUSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has closed its previously announced registered direct offeri
4y agoARAVAravive Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdatesGlobeNewswireReported positive data from Phase 1b trials of batiraxcept in clear cell renal cell carcinoma and pancreatic adenocarcinoma in 1Q'22; on track to report updated data in 2Q'22 Dosed first patient in Phase 2 trial of batiraxcept in ccRCC in January 2022;
4y agoARAVAravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswireHOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced today that it has entered into definitive agreements with a single h
4y agoARAVAravive Appoints Scott Dove, Ph.D., as Chief Operating OfficerGlobeNewswireHOUSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of industry veteran, Scott Dove, Ph.D., as Chi
4y agoARAVAravive to Participate In-Person at 34th Annual ROTH ConferenceGlobeNewswireHOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive,
4y agoARAVAravive Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell CarcinomaGlobeNewswire46% Best Overall Response Rate in the ITT Population 63% Best Overall Response Rate in the sAXL/GAS6 Biomarker High Population 6-month Progression-Free Survival Rate in the ITT Population of 79% 6-month Progression-Free Survival Rate of 91%
4y agoARAVAravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual MeetingGlobeNewswireHOUSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, will present updated exposure-response analyses from the Phase 1b platinum-res
4y agoARAVAravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell CarcinomaGlobeNewswireHOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that the Company has dosed the first patient in the Phase 2 por
4y agoARAVAravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of DirectorsGlobeNewswireHOUSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the company's Chairman, Fred Eshelman, Pharm.D., through Es
4y agoARAVAravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare ConferenceGlobeNewswireHOUSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that Gail McIntyre, Ph.D., DABT, Chief Executi
5y agoARAVAravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell CarcinomaGlobeNewswire7 of 16 (44%) patients achieved best overall response of partial responseConfirmed response in 5 of 7 (71%) patients who had at least 16 weeks of follow-up14 of 16 (88%) patients demonstrated tumor decrease from baselineBatiraxcept has been well-tolerate
5y agoARAVAravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual MeetingGlobeNewswire3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baselineBatiraxcept has been generally well-tolerated with no dose-limiting toxicitiesAravive to host conference call and webcast on November 12 at
5y agoARAVAravive Reports Third Quarter 2021 Financial Results and Provides Corporate UpdatesGlobeNewswireDosed first patient in batiraxcept (formerly AVB-500) Phase 1b clinical trial in pancreatic adenocarcinoma Orphan drug designation granted by European Commission to batiraxcept in platinum resistant ovarian cancer New preliminary data from batiraxcept
5y agoARAV EVLO GRCL HGEN+1Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of DirectorsBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced today that the Company's Board of Directors (the "Board") has electe
5y agoARAVAravive to Present New Preliminary Data from Phase 1b Trial Evaluating AVB-500 in Clear Cell Renal Cell Carcinoma at 2021 Society for Immunotherapy of Cancer Annual MeetingGlobeNewswireHOUSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that new preliminary safety, pharmacokinetic, pharmacodynam
5y agoARAVAravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare ConferenceGlobeNewswireHOUSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer o
5y agoARAVAravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireHOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer o
5y agoARAVAravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic AdenocarcinomaGlobeNewswireTrial to Evaluate AVB-500 as a First-Line Treatment in Combination with Gemcitabine and Nab-Paclitaxel Continues Expansion of AVB-500 in Multiple Oncology Indications and Combinations HOUSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (NASDA